Heptares Therapeutics is an established UK biotech company with world-class technology in structure-based drug design applied to discovery of novel small molecules acting through GPCRs.
The company works in collaboration with major global pharmaceutical companies on both small molecule and antibody discovery programmes, and is also developing its own pipeline of novel small molecules and peptides.
The most advanced of these is now in Phase I clinical studies with others moving towards clinical development.
The company is currently based in Welwyn Garden City, has approximately 100 employees, and has been operating for nine years.
The size of the company ensures a transparent linkage between all activities from early discovery through to clinical development.
As a result of the increased activities in building its own pipeline we now seek to recruit a highly motivated DMPK Project Leader (Senior Scientist II grade) who will work alongside the Head of DMPK to support Heptares projects throughout discovery phases up to pre-clinical candidate (PCC) selection.
This is an exciting opportunity to work across a broad range of therapeutic areas and project chemistries, which includes both small molecules and peptides.
The candidate will have a strong background in DMPK and a sound understanding of in vitro ADME and PK principles based on direct experience working within CRO, Biotech or Pharmaceutical environments.
The role will provide opportunity to work directly with a network of external DMPK suppliers (CROs) and consultants.
The ideal candidate will be familiar with best practice approaches for dealing with external suppliers, defining DMPK structure-property relationships and providing guidance on discovery DMPK related matters.
Dependent on experience there is scope in the role to deliver the overall non-clinical drug disposition contribution to drug discovery projects.
We are seeking candidates whose profile will include:
・Appropriate years of experience within a DMPK related scientific discipline, ideally from within an industry based drug discovery environment.
・Proven track record of supporting and/or leading DMPK-related activities and ensuring project ADME challenges are thoroughly assessed and resolved during lead identification to PCC selection phases.
・Collaborating effectively with Medicinal Chemistry, Pharmacology and CRO’s to plan and oversee delivery of routine, as well as bespoke, in vitro ADME/PK studies supporting compound design, selection and project progression.
・Analysis of in vitro ADME and in vivo pharmacokinetic data in relation to chemical structure to help understand DMPK, safety and efficacy related issues. In close collaboration with the Head of DMPK implement strategies that optimise the overall properties of novel compounds.
・Familiarity in the design and analysis of experiments to define quantitative preclinical PK/PD/efficacy relationships.
・Strong problem solving, data mining, visualisation and interpretation skills.
・Effective written and oral communication, and proactive follow-through and engagement with all project team representatives and other stakeholders.
・Experience of developing pre-clinical formulations to support PK and PKPD studies desirable.
・Experience of leveraging PBPK and/or PKPD modelling software (such as WinNonLin or Gastro-Plus) to support an early understanding of predicted human PK and dose desirable.
The closing date for applications is 29th September
※HEPTARES Careers update
Company: Heptares Therapeutics
Published:31-Aug-2016
Heptares Therapeutics is an established UK biotech company with world-class technology in structure-based drug design applied to discovery of novel small molecules acting through GPCRs.
The company works in collaboration with major global pharmaceutical companies on both small molecule and antibody discovery programmes, and is also developing its own pipeline of novel small molecules and peptides.
The most advanced of these is now in Phase I clinical studies with others moving towards clinical development.
The company is currently based in Welwyn Garden City, has approximately 100 employees, and has been operating for nine years.
The size of the company ensures a transparent linkage between all activities from early discovery through to clinical development.
As a result of the increased activities in building its own pipeline we now seek to recruit a highly motivated DMPK Project Leader (Senior Scientist II grade) who will work alongside the Head of DMPK to support Heptares projects throughout discovery phases up to pre-clinical candidate (PCC) selection.
This is an exciting opportunity to work across a broad range of therapeutic areas and project chemistries, which includes both small molecules and peptides.
The candidate will have a strong background in DMPK and a sound understanding of in vitro ADME and PK principles based on direct experience working within CRO, Biotech or Pharmaceutical environments.
The role will provide opportunity to work directly with a network of external DMPK suppliers (CROs) and consultants.
The ideal candidate will be familiar with best practice approaches for dealing with external suppliers, defining DMPK structure-property relationships and providing guidance on discovery DMPK related matters.
Dependent on experience there is scope in the role to deliver the overall non-clinical drug disposition contribution to drug discovery projects.
We are seeking candidates whose profile will include:
・Appropriate years of experience within a DMPK related scientific discipline, ideally from within an industry based drug discovery environment.
・Proven track record of supporting and/or leading DMPK-related activities and ensuring project ADME challenges are thoroughly assessed and resolved during lead identification to PCC selection phases.
・Collaborating effectively with Medicinal Chemistry, Pharmacology and CRO’s to plan and oversee delivery of routine, as well as bespoke, in vitro ADME/PK studies supporting compound design, selection and project progression.
・Analysis of in vitro ADME and in vivo pharmacokinetic data in relation to chemical structure to help understand DMPK, safety and efficacy related issues. In close collaboration with the Head of DMPK implement strategies that optimise the overall properties of novel compounds.
・Familiarity in the design and analysis of experiments to define quantitative preclinical PK/PD/efficacy relationships.
・Strong problem solving, data mining, visualisation and interpretation skills.
・Effective written and oral communication, and proactive follow-through and engagement with all project team representatives and other stakeholders.
・Experience of developing pre-clinical formulations to support PK and PKPD studies desirable.
・Experience of leveraging PBPK and/or PKPD modelling software (such as WinNonLin or Gastro-Plus) to support an early understanding of predicted human PK and dose desirable.
The closing date for applications is 29th September